Marshall Wace LLP Cuts Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Marshall Wace LLP trimmed its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 40.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,017,539 shares of the biotechnology company's stock after selling 698,006 shares during the period. Marshall Wace LLP owned approximately 0.67% of Heron Therapeutics worth $1,557,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Barclays PLC grew its holdings in shares of Heron Therapeutics by 10.5% during the fourth quarter. Barclays PLC now owns 241,346 shares of the biotechnology company's stock worth $370,000 after purchasing an additional 22,891 shares during the last quarter. Quinn Opportunity Partners LLC acquired a new stake in shares of Heron Therapeutics in the 4th quarter valued at about $581,000. Raymond James Financial Inc. purchased a new position in Heron Therapeutics during the 4th quarter worth approximately $208,000. Invesco Ltd. grew its stake in Heron Therapeutics by 38.2% during the 4th quarter. Invesco Ltd. now owns 71,399 shares of the biotechnology company's stock worth $109,000 after buying an additional 19,738 shares during the last quarter. Finally, Aristides Capital LLC acquired a new position in Heron Therapeutics during the fourth quarter worth approximately $81,000. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Needham & Company LLC restated a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, April 11th. StockNews.com downgraded shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th.

Heron Therapeutics Stock Down 1.7 %

HRTX traded down $0.04 on Friday, hitting $2.31. 1,458,539 shares of the company traded hands, compared to its average volume of 2,306,930. Heron Therapeutics, Inc. has a 12-month low of $1.04 and a 12-month high of $3.93. The company has a 50 day moving average of $2.18 and a 200-day moving average of $1.80. The stock has a market capitalization of $351.88 million, a PE ratio of -12.83 and a beta of 1.39.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.05. The company had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. On average, research analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.